Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NCT04227106
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
11
Enrollment
INDUSTRY
Sponsor class
Conditions
Epidermolysis Bullosa
Recessive Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL:
EB-101
Sponsor
Abeona Therapeutics, Inc